Van Andel Institute Chief Scientific Officer Peter A. Jones, Ph.D., D.Sc. (hon), has been elected to the National Academy of ...

A recent study evaluates the dosing, safety, and efficacy of telaglenastat and azacytidine to treat advanced myelodysplastic syndromes (MDS), with promising results. Cancer cells, particularly ...

The US Food and Drug Administration approved 5-azacytidine for the treatment of MDS in 2004. The drug improves bone marrow function by freeing up the genes the body needs to make normal blood cells.

By combining CB-839 with azacytidine, a drug that kills rapidly dividing cells and is typically used to treat MDS, researchers saw promising results for patients with one of the most common types of ...

New research from the Royal College of Surgeons in Ireland has found that venetoclax, a medication currently approved for leukemia, provides benefits for patients with multiple myeloma when used in ...

When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase ...

Two examples of these types of drugs are 5-azacytidine and 5-aza-2′-deoxycytidine (Egger et al., 2004). These medications work by acting like the nucleotide cytosine and incorporating themselves ...

Ribonucleosides such as 5-azacytidine or zebularine are reduced at the diphosphate level by ribonucleotide reductase for incorporation (not shown). Once in DNA, the fraudulent bases form covalent ...

RCSI research has found that venetoclax, a medication currently approved for leukemia, has benefits for patients with multiple myeloma when used in combination with another drug. This discovery offers ...

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ...